Influence of trimetazidine on cardiac function in patients with ischemic cardiomyopathy
JIANG Ming-hong
WANG Xia
LIU Ya-zhong
CAO Xue-bin
Abstract：Objective To review the influence of trimetazidine on exercise tolerance of cardiac function in the patients with ischemic cardiomyopathy. Methods The patients (n=52) with ischemic cardiomyopathy were chosen from Oct. 2010 to Jun. 2011, and then randomly divided into observation group and treatment group (each n=26). The observation group was given traditional drugs including β-blocker, ACE inhibitor, diuretics, aldosterone antagonist and digitalis for 6 months, and treatment group was additionally given trimetazidine (20 mg/tid) for 6 months. The left ventricular function (LVEDD, LVEF and 6MWT) and BNP level were reviewed in two groups before and after the treatment. Results The cardiac function was improved in two groups after the treatment. Compared with observation group, LVEF increased [(47.46±9.28)% vs. (41.35±7.66)%], LVEDD decreased [(49.50±4.38) mm vs. (59.38±6.85) mm], 6MWT increased [508.83±204.61) m vs. (278.49±106.78) m] and BNP decreased significantly [(1925.00±1287.20) pg/mL vs. (3873.01±3333.59) pg/mL] in treatment group (P<0.05). Conclusion Trimetazidine integrated with routine drugs can significantly improve cardiac function and exercise tolerance in the patients with ischemic cardiomyopathy.
Keywords：Ischemic cardiomyopathyTrimetazidineCardiac function
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 380-382 )